Live Analyst Rating Changes 36595 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Daniel Clark
LP

Daniel Clark

Leerink Partners
Wall Street Analyst
★☆☆☆☆
#2970
on 13Foresight · ranked by our own returns
44%
Success Rate
-7.0%
Average Return
7 of 16 calls profitable · +15.7% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 44% of Daniel Clark's ratings turned a profit when each position was held for 1 year — averaging -7.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

14 Buy 4 Hold 0 Sell
Daniel's Stock Coverage 11 ratings · 2026-10-02
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
ELAN
Elanco Animal Health
 Oct 01, 2026 BUY Strong Buy
+43.8% avg upside
18 analysts
$34.00
56.13% Upside
 +1.7% ·
ZTS
Zoetis
 Oct 01, 2026 HOLD Buy
+71.7% avg upside
23 analysts
 — +0.8% ·
AMRX
Amneal Pharmaceuticals
 Sep 17, 2026 BUY Buy
-5.1% avg upside
19 analysts
$23.00
14.64% Upside
 +9.8% ·
ANIP
ANI Pharmaceuticals
 Sep 09, 2026 BUY Strong Buy
+38.8% avg upside
12 analysts
$104.00
42.50% Upside
 +5.8% ·
COLL
Collegium Pharmaceutical
 Sep 09, 2026 BUY Strong Buy
+91.2% avg upside
10 analysts
$45.00
106.04% Upside
 -3.5% ·
PHAT
Phathom Pharmaceuticals
 Sep 09, 2026 HOLD Strong Buy
+249.6% avg upside
15 analysts
$10.00
41.15% Upside
 -15.8% ·
BLCO
Bausch + Lomb Corporation
 Sep 09, 2026 BUY Buy
+18.9% avg upside
20 analysts
$24.00
41.77% Upside
 -3.5% ·
HROW
Harrow Health
 Sep 09, 2026 BUY Strong Buy
+74.0% avg upside
13 analysts
$45.00
47.05% Upside
 -14.2% ·
VTRS
Viatris
 Sep 09, 2026 BUY Buy
+34.0% avg upside
22 analysts
$20.00
14.49% Upside
 +6.7% ·
PCRX
Pacira Pharmaceuticals
 Sep 09, 2026 HOLD Buy
+51.5% avg upside
22 analysts
$28.00
11.95% Upside
 -3.2% ·
IDXX
Idexx Laboratories
 Nov 03, 2025 BUY Buy
+39.1% avg upside
17 analysts
$785.00
51.54% Upside
 -26.8% ·
🔒 6 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Daniel Clark — Frequently Asked Questions
How accurate are Daniel Clark's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Daniel's ratings were profitable over a one-year hold, with an average return of -6.9% per rating, or +15.8% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Daniel ranked on 13Foresight?
Daniel Clark is currently ranked #2970 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Daniel cover?
Daniel most recently has ratings on ELAN, ZTS, AMRX, ANIP, COLL, PHAT, BLCO, HROW, VTRS, PCRX, IDXX. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.